铋剂四联三合一单胶囊每日三次方案较常规每日四次方案提高幽门螺杆菌根除效果:来自欧洲幽门螺杆菌管理登记研究(Hp-EuReg)的结果
该研究基于欧洲幽门螺杆菌管理登记研究(Hp-EuReg)中2013年6月至2021年3月登记的3712例西班牙成年患者,比较10天铋剂四联三合一单胶囊方案每日三次与每日四次的有效性、依从性和安全性。每日三次组根除率显著高于每日四次组(94% vs 91%,p=0.002),依从性和安全性相似。多因素分析显示每日三次给药、初治、使用标准或高剂量PPI及依从性超过90%与根除成功显著相关。
要点
- 每日三次铋剂四联单胶囊方案根除率显著高于每日四次方案(94% vs 91%,p=0.002)。
- 两种方案的依从性和安全性数据相似。
- 每日三次给药、初治、标准或高剂量PPI及依从性超过90%与根除成功显著相关。
核心结论
- 每日三次铋剂四联三合一单胶囊方案比传统每日四次方案更有效,治疗依从性和安全性无差异。
研究设计与样本
- 基于欧洲幽门螺杆菌管理登记研究(Hp-EuReg)的西班牙成人患者数据分析,纳入2013年6月至2021年3月登记并接受10天铋剂四联三合一单胶囊方案者,共3712例。
- 采用改良意向性治疗分析比较每日三次与每日四次方案的有效性、依从性和安全性,并进行多因素分析确定根除感染的独立预测因素。
主要发现
- 3712例中每日四次方案2516例(68%),每日三次方案1196例(32%);平均年龄51岁,女性占63%,15%有消化性溃疡。
- 每日三次方案总体根除率显著优于每日四次方案(1047/1112,94%;95%CI 92.7至95.6 vs 2207/2423,91%;95%CI 89.9至92.2,p=0.002)。
- 两种方案的依从性和安全性数据相似。
- 多因素分析中,每日三次给药、初治、使用标准或高剂量PPI及依从性超过90%与感染根除显著相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The recommended schedule for single capsule bismuth quadruple therapy (scBQT, Pylera) includes a proton pump inhibitor (PPI) two times a day and three scBQT capsules four times a day. Four times a day treatments are inconvenient and reduce adherence. In contrast, adherence improves with three times a day schedules. In clinical practice, many gastroenterologists use four capsule scBQT three times a day. However, the effectiveness and safety of this latter approach remain uncertain. AIM: To assess the effectiveness and safety of scBQT administered three times a day in the patients included in the European Registry on Helicobacter pylori Management (Hp-EuReg). METHODS: All Spanish adult patients registered in the Asociación Española de Gastroenterología Research Electronic Data Capture (REDCap) database from June 2013 to March 2021 receiving 10-day scBQT were analysed. Modified intention-to-treat effectiveness, adherence and the safety of scBQT given three times a day were calculated and compared with the four times a day schedule. A multivariate analysis was performed to determine independent factors predicting cure of the infection. RESULTS: Of the 3712 cases, 2516 (68%) were four times a day and 1196 (32%) three times a day. Mean age was 51 years, 63% were women and 15% had a peptic ulcer. The three times a day schedule showed significantly better overall cure rates than four times a day (1047/1112, 94%; 95% CI 92.7 to 95.6 vs 2207/2423, 91%; 95% CI 89.9 to 92.2, respectively, p=0.002). Adherence and safety data were similar for both regimens. In the multivariate analysis, three times a day dosage, first-line therapy, use of standard or high-dose PPIs and adherence over 90% were significantly associated with cure of the infection. CONCLUSIONS: ScBQT prescribed three times a day was more effective than the traditional four times a day schedule. No differences were observed in treatment adherence or safety.
引用
- Pérez-Aisa Á, Nyssen OP, Keco-Huerga A, et al. Bismuth quadruple three-in-one single capsule three times a day increases effectiveness compared with the usual four times a day schedule: results from the European Registry on Helicobacter pylori Management (Hp-EuReg). Gut. 2023. PMID: 37468228. doi:10.1136/gutjnl-2022-329259
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。